WitrynaImmix Biopharma, Inc - Tissue-Specific Therapeutics (TSTx) Targeting Oncology & Immuno-Dysregulated Diseases - Tissue-Specific Therapeutics (TSTx) Targeting … WitrynaAt Immix Biopharma, our SMARxT Tissue-Specific Platform produces Tissue-Specific Therapies (TSTx), which in cancer target all 3 components of the TME …
Nexcella, an Immix Biopharma Subsidiary, Announces 2024 …
Witryna28 mar 2024 · Immix Biopharma, Inc. (NADSAQ:IMMX) Strategy Analyst Position. Existing Pipeline - Participate in determining development strategy for existing … Witryna5 kwi 2024 · Immix Biopharma, Inc. (ImmixBio™) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific … howard issacson phila
Immix Biopharma — Expanding portfolio into CAR-T cell therapy
Witryna31 mar 2024 · LOS ANGELES, March 31, 2024 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that an editorial written by Maria Sjöstrand and Michel Sadelain of Memorial Sloan Kettering Cancer Center was published 2024 in Haematologica … Witryna14 gru 2024 · Immix Biopharma has formed a wholly-owned subsidiary, Nexcella, Inc., to develop and potentially commercialize NXC-201. Low-grade (grade 1/2) CRS duration of median 2 days with median onset of 1 ... WitrynaDec-15-21 06:00PM. Immix Biopharma, Inc. Announces Pricing of Initial Public Offering. GlobeNewswire. Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in … howard i. ungerleider dow chemical company